同和藥業(300636.SZ):向不特定對象發行不超3.6億元可轉債申請獲證監會同意註冊批覆
格隆匯 9 月 24日丨同和藥業(300636.SZ)公佈,公司擬向不特定對象發行數量不超過360萬張、募集資金總額不超過3.6億元的可轉換公司債券,公司於2020年9月23日收到中國證券監督管理委員會(以下簡稱“中國證監會”)出具的《關於同意江西同和藥業股份有限公司向不特定對象發行可轉換公司債券註冊的批覆》(證監許可[2020]2259號),批覆具體內容如下:
一、同意公司向不特定對象發行可轉換公司債券的註冊申請。
二、公司本次發行應嚴格按照報送深圳證券交易所的申報文件和發行方案實施。
三、本批覆自同意註冊之日起12個月內有效。
四、自同意註冊之日起至本次發行結束前,公司如發生重大事項,應及時報告深圳證券交易所並按有關規定處理。
公司董事會將根據上述文件和相關法律法規的要求及公司股東大會的授權,在規定期限內辦理本次向不特定對象發行可轉換公司債券相關事宜,並及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.